Repairable ex vivo model of functional and degenerative mitral regurgitation
European Journal of Cardio-Thoracic Surgery · 2023
DOI: 10.1093/ejcts/ezad371 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2023. Verfasst von Hayato Morimura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cooperative Major in Advanced Biomedical Sciences, Joint Graduate School of Tokyo Women's Medical University and Waseda University, Waseda University…. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Cardiac Surgical Procedures, Heart Valve Prosthesis Implantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
OBJECTIVES Transcatheter mitral valve repair is an emerging alternative to the surgical repair. This technology requires preclinical studies to assess efficacy in mitigating mitral regurgitation (MR). However, ex vivo MR models are not established. We developed 2 novel repairable models, functional and degenerative, which can quantitatively assess regurgitation and effect of intervention. METHODS We used porcine mitral valves and a pulsatile flow circulation system. In the functional MR model, the annulus was immersed in 0.1% collagenase solution and dilated using 3D-printed dilators. To control the regurgitation grade, the sizes of the dilator and silicone sheet in which the valve was sutured to were adjusted. Chordae of P2 were severed in the degenerative model, and the number of severed chordae was adjusted to control the regurgitation grade. Models were repaired using the edge-to-edge or artificial chordae technique. RESULTS The mean regurgitant fraction of the moderate–severe functional and degenerative models were 47.9% [standard deviation (SD): 2.2%] and 58.5% (SD: 8.0%), which were significantly reduced to 28.7% (SD: 4.4%) (P < 0.001) and 26.0% (SD: 4.4%) (P < 0.001) after the valve repair procedures. Severe functional model had a mean regurgitant fraction of 59.4% (SD: 6.0%). CONCLUSIONS Both functional and degenerative models could produce sufficient MR levels that meet the interventional indication criteria. The repairable models are valuable in evaluating the efficacy of valve repair procedures and devices. The ability to control the amount of regurgitation enhances the versatility and reliability of these models. These reproducible models could expedite the development of novel devices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cooperative Major in Advanced Biomedical Sciences, Joint Graduate School of Tokyo Women's Medical University and Waseda University, Waseda University, Tokyo, Japan.
- Department of Modern Mechanical Engineering, Graduate School of Creative Science and Engineering, Waseda University, Tokyo, Japan.
- Department of Integrative Bioscience and Biomedical Engineering, Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan.
- Department of Cardiovascular Surgery, Juntendo University, Tokyo, Japan.
- Institute for Medical Regulatory Science, Waseda University, Tokyo, Japan.
ORCID-Profile: Hayato Morimura, Minoru Tabata, Kiyotaka Iwasaki
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Morimura, H., Okamoto, Y., Takada, J., Tabata, M., & Iwasaki, K. (2023). Repairable ex vivo model of functional and degenerative mitral regurgitation. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezad371
Vancouver
Morimura H, Okamoto Y, Takada J, Tabata M, Iwasaki K. Repairable ex vivo model of functional and degenerative mitral regurgitation. European Journal of Cardio-Thoracic Surgery. 2023. doi:10.1093/ejcts/ezad371
BibTeX
@article{Morimura2023,
author = {Morimura, Hayato and Okamoto, Yusei and Takada, Jumpei and Tabata, Minoru and Iwasaki, Kiyotaka},
title = {Repairable ex vivo model of functional and degenerative mitral regurgitation},
journal = {European Journal of Cardio-Thoracic Surgery},
year = {2023},
doi = {10.1093/ejcts/ezad371}
}
EUVIMED